Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
Type:
Grant
Filed:
November 6, 2007
Date of Patent:
August 17, 2010
Assignee:
Duke University
Inventors:
Bruce A. Sullenger, Christopher P. Rusconi
Abstract: The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGF?, or using agents that inhibit TGF? in combination with agents that degrade excess accumulated extracellular matrix, or at least one agent that degrades excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of FR-alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
Type:
Grant
Filed:
October 26, 2007
Date of Patent:
June 22, 2010
Assignee:
Duke University
Inventors:
Bruce A. Sullenger, Christopher P. Rusconi
Abstract: The invention provides for antisense oligonucleotides that hybridize to casein kinase 2 nucleic acid sequences and methods of using such antisense oligonucleotides to inhibit expression of casein kinase 2 and reduce the size of solid tumors.
Type:
Grant
Filed:
June 14, 2007
Date of Patent:
June 22, 2010
Assignee:
Regents of The University of Minnesota
Inventors:
Joel W. Slaton, Khalil Ahmed, Gretchen M. Unger, Alan Davis, Dan Sloper
Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
Type:
Grant
Filed:
March 9, 2009
Date of Patent:
May 25, 2010
Assignee:
Alnylam Pharmaceuticals, Inc.
Inventors:
Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
Type:
Grant
Filed:
June 16, 2008
Date of Patent:
May 18, 2010
Assignee:
Novartis AG
Inventors:
Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
Abstract: The present invention provides three BCAS2 related nucleotide sequences. The present invention also provides a composition comprising a nucleotide sequence of small interfering RNA of BCAS2 gene. The present invention further provides a method for treating p53 containing cancer comprising administrating a subject with an effective amount of the said composition.
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
Abstract: The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of agents that inhibit TGF?, or using agents that inhibit TGF? in combination with agents that degrade excess accumulated extracellular matrix. The compositions and methods of the invention are used to treat conditions such as fibrotic diseases and scarring that result from excess accumulation of extracellular matrix, impairing tissue or organ function or skin appearance in a subject.
Type:
Grant
Filed:
July 8, 2004
Date of Patent:
May 11, 2010
Assignees:
University of Utah Research Foundation, The American National Red Cross
Inventors:
Nancy A. Noble, Wayne A. Border, Daniel A. Lawrence
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.
Type:
Grant
Filed:
January 28, 2008
Date of Patent:
May 4, 2010
Assignee:
ISIS Pharmaceuticals, Inc.
Inventors:
William Gaarde, Andrew T Watt, Brett P Monia, Mausumee Guha
Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2?-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates.
Abstract: The invention relates to the treatment of renal diseases using modulators of integrin linked kinase. Methods of treatment as well as therapeutic agents including antisense, small molecules, catalytic peptides and antibodies are disclosed. The agents of the invention may also be used in combination with traditional therapies for renal disease including ACE inhibitors. An advantage of the invention is that it treats one of the causes of renal disease, rather than just ameliorating symptoms, and can help prevent the progression of renal disease to the point of acute renal failure.
Abstract: The invention relates to a synthetic double-stranded oligonucleotide capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene. Pharmaceutical compositions comprising the oligonucleotide according to the invention are also described, as well as therapeutic applications of that oligonucleotide, in particular for the treatment of osteopenic diseases such as for example osteoporosis. The oligonucleotide according to the invention is characterized in that it comprises the sequence 5?-ATTTATTTTCAATACTGACT-3? (SEQ ID NO: 1) or a fragment or a mutant thereof.
Type:
Grant
Filed:
March 30, 2006
Date of Patent:
February 9, 2010
Assignees:
Universita' Degli Studi di Ferrara, Associazione Veneta per la Lotta Alla Talassemia
Inventors:
Roberto Gambari, Letizia Penolazzi, Roberta Piva
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TRPV1.
Type:
Grant
Filed:
October 26, 2007
Date of Patent:
February 2, 2010
Assignee:
Dharmacon, Inc.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Novel methods of regulating cellular apoptosis by affecting the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin are described. More specifically, these novel methods of enhancing apoptosis of neoplastic cells comprises inhibiting interaction of hepatitis B X-interacting protein (HBXIP) with Survivin using siRNA or antisense compounds.
Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 15454 GAM precursors oligonucleotides, and 681 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.